IL-2 upregulates CD86 expression on human CD4(+) and CD8(+) T cells

Area of Science:

• Immunology
• Molecular Biology
• Cellular Signaling

Background:

• CD86 is a key costimulatory molecule primarily found on antigen-presenting cells (APCs).
• Recent findings indicate CD86 expression on T cells under certain pathological conditions.
• The mechanisms and functional significance of CD86 on T cells remain largely unelucidated.

Purpose of the Study:

• To investigate the mechanisms by which CD86 is induced on T cells.
• To determine the role of Interleukin-2 (IL-2) in regulating CD86 expression on human T cells.
• To explore the signaling pathways involved in IL-2-mediated CD86 upregulation.

Main Methods:

• Treatment of isolated human CD4(+) and CD8(+) T cells with IL-2.
• Assessment of CD86 and CD80 expression using flow cytometry.
• Inhibition studies using antibodies against IL-2 and IL-2 receptor alpha (CD25).
• Pharmacological inhibition of NFAT and mammalian target of rapamycin (mTOR) pathways.
• Analysis of T cell responses in IL-2-treated patients.

Main Results:

• IL-2 treatment markedly upregulated CD86, but not CD80, on human CD4(+) and CD8(+) T cells.
• CD86 upregulation was a receptor-mediated process involving IL-2 and IL-2Rα (CD25).
• The upregulation was dependent on NFAT and mTOR signaling pathways and partially inhibited by IFN-α.
• Increased CD86 expression on T cells was confirmed in vivo in IL-2-treated patients.

Conclusions:

• IL-2 is a significant inducer of CD86 expression on human CD4(+) and CD8(+) T cells.
• The mechanism is receptor-dependent and involves the activation of NFAT and mTOR signaling.
• These findings provide insights into the regulation of CD86 on T cells and its potential role in IL-2-mediated immune responses.